This locally developed innovation in Hong Kong addresses longstanding industry challenges in gender determination for twin pregnancies. It overcomes the limitations of traditional qPCR platforms, achieving the first-ever precise identification of male-female twins while significantly enhancing the accuracy of fetal cell-free DNA (cfDNA) analysis.

Traditional methods could only qualitatively detect the presence of the Y chromosome, failing to distinguish between male-male twins and male-female twins. They also lacked the capability to identify residual male cfDNA after fetal reduction procedures. Zentrogene's NGS-based technology achieves three breakthroughs:

1. Fetal Signal Assessment: Utilizes whole-genome SNP scanning to confirm fetal signal presence, precisely quantify fetal fraction, and determine the number of fetal signals.
2. Contamination Identification: Differentiates between false signals (e.g., contamination-derived Y chromosome fragments) and true fetal signals.
3. Twin Pregnancy Precision Analysis: Independently analyzes X and Y chromosome fragments to accurately distinguish male-female twins from male-male twins.

As a pioneer in Hong Kong's genetic testing field, Zentrogene has established a global technology matrix covering pre-pregnancy, prenatal, and oncology applications through its integrated Sanger sequencing and NGS platforms. This NGS breakthrough underscores its 'Technology-Driven Globalization' strategy, leveraging Hong Kong's expertise to deliver precision medical solutions worldwide. Zentrogene continues to advance genetic technology, safeguarding every family's hopes with scientific rigor.

For details, visit:
https://www.zentrogene.com/
https://www.zentrogene.com.hk/

Official Cooperation Contacts:
Telephone: +86 18051865085 (WeChat same number)
Telegram: +855 99990026
Facebook: Zentrogene

Hashtag: #Zentrogene

The issuer is solely responsible for the content of this announcement.

• Prev
• Next